09:18 AM EDT, 04/17/2024 (MT Newswires) -- GSK (GSK) on Wednesday reported positive results from phase 3 trials for gepotidacin, an oral antibiotic to treat urogenital gonorrhea, and Shingrix, its shingles vaccine.

The drug maker said gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment and that safety and tolerability were consistent with phase 1 and 2 trials.

Separately, a long-term follow-up trial showed that Shingrix, GSK's shingles vaccine, maintained 79.7% efficacy in participants aged 50 and above, six to 11 years post-vaccination.

GSK said the efficacy of the vaccine remained high at 82% even 11 years after the initial vaccination.